Calidi Biotherapeutics unveiled preclinical findings for its RedTail virotherapy platform at the 2026 AACR-IO Conference, demonstrating a novel approach to delivering bispecific T-cell engagers (BiTEs) and IL-15 superagonist directly to solid tumors. The platform addresses a significant challenge in immuno-oncology, as conventional BiTE therapies have shown limited efficacy in solid tumors due to immunosuppressive microenvironments and restricted T-cell infiltration.
The RedTail platform enables systemic administration of therapeutic agents while directing their accumulation at tumor sites, potentially improving both efficacy and tolerability compared to existing approaches. By combining BiTE technology with immune-modulating cytokines, Calidi's strategy seeks to simultaneously remodel the tumor microenvironment and enhance T-cell activation at the disease site, addressing two critical barriers to effective immunotherapy in solid malignancies.
The company is currently executing investigational new drug (IND)-enabling studies for its lead candidate, CLD-401, with plans to submit an IND application to the FDA by the end of 2026. This timeline positions Calidi to advance into clinical evaluation pending regulatory clearance.